BRUSSELS, Belgium, May 19, 2026
SERB Pharmaceuticals and Hansa Biopharma have announced a strategic €115 million licensing agreement granting SERB exclusive development and commercialization rights to Idefirix® (imlifidase) across Europe, the United Kingdom, Switzerland, Norway, Iceland, Liechtenstein, and the Middle East and North Africa (MENA) region. The deal strengthens SERB’s growing rare disease portfolio while significantly expanding access to a differentiated kidney transplant therapy designed for highly sensitized patients facing severe immunological barriers to transplantation.
The agreement marks one of the notable rare disease licensing transactions of 2026 and reflects increasing pharmaceutical industry investment in specialized transplant therapeutics and immunology-focused commercialization strategies. Under the terms of the transaction, Hansa Biopharma will receive an upfront payment of €110 million plus an additional €5 million milestone payment tied to the acceptance of a filing for full European Medicines Agency (EMA) approval.
Idefirix Expands Access for Highly Sensitized Kidney Patients
Idefirix® (imlifidase) is a first-in-class antibody-cleaving enzyme therapy developed to help highly sensitized adult kidney transplant patients receive compatible donor organs. These patients often carry pre-formed reactive IgG antibodies capable of attacking donor tissue, dramatically increasing the risk of immediate antibody-mediated rejection. As a result, many patients remain on dialysis for years while waiting for a suitable donor match.
According to the companies, approximately 70,000 people in Europe await kidney transplantation annually, with an estimated 10–15% classified as highly sensitized, making transplantation significantly more difficult. SERB Pharmaceuticals stated that the acquisition aligns with its mission of delivering therapies for rare and urgent medical conditions with limited treatment alternatives.
Advertisement
Idefirix works by rapidly cleaving immunoglobulin G (IgG) antibodies, thereby reducing immune system activity that would otherwise trigger rejection of a donor kidney. The therapy acts within hours after administration and is currently conditionally approved in the European Union and several European markets for desensitization treatment in highly sensitized adult kidney transplant recipients with positive crossmatch tests against deceased donors.
Strategic Licensing Deal Strengthens Rare Disease Portfolios
The transaction highlights the continued expansion of pharmaceutical licensing and commercialization partnerships focused on rare diseases and specialty medicine markets. SERB will assume responsibility for long-term post-authorization efficacy studies (PAES) and ongoing pediatric development programs after becoming the market authorization holder. Hansa Biopharma will continue supporting the regulatory filing and EMA review process as additional post-authorization data become available.
Completion of the transaction remains subject to customary foreign direct investment (FDI) regulatory approvals, which are expected to conclude within approximately 60 days.
Industry analysts view the agreement as strategically important because it enables SERB to broaden its footprint in transplantation and rare immunological conditions while allowing Hansa Biopharma to strengthen its financial position and focus on global expansion opportunities. In the United States, the U.S. FDA accepted the Biologics License Application (BLA) for imlifidase earlier this year and assigned a Prescription Drug User Fee Act (PDUFA) action date of December 19, 2026.
Rare Disease Innovation Continues to Attract Investment
The acquisition underscores growing commercial interest in rare disease therapies capable of addressing high unmet medical needs. Highly sensitized kidney transplant patients remain one of the most underserved groups in transplantation medicine due to elevated immunological risks and prolonged waiting periods for compatible donor organs.
With global healthcare systems increasingly prioritizing precision medicine and specialized transplant therapies, the SERB-Hansa transaction reflects broader pharmaceutical industry momentum toward strategic licensing agreements targeting orphan and rare disease markets.
Source: SERB Pharmaceuticals, Hansa Biopharma press release
